Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

NCT07468552 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and highest tolerable dose of the medication tirzepatide in adults with cannabis use disorder.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-11 · est. completion 2028-11

What this study is testing ClinicalTrials.gov NCT07468552 ↗

Description as written by the study sponsor.

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Treatments tested

Tirzepatide Drug

Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will be made based on the Dose Increase Checklist and shared decision between the site study physician (MD or DO) and the participant.
Placebo Drug

Participants will receive weekly masked injections of placebo.

Main thing measured	Maximum Tolerated Dose (MTD)
Sponsor	National Institute on Drug Abuse (NIDA)
Conditions studied	Cannabis Use Disorder
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07468552 ↗